July 18 2017 – ORAMED Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today the appointment of Dr. Simon Bruce MD to the newly created position of Vice President of Medical Affairs.
“We are very pleased to welcome Dr. Bruce on board at this pivotal time for ORAMED as we prepare for the initiation of a Phase III trial for our oral insulin capsule, ORMD-0801. Dr. Bruce will be tasked with leading all of our clinical development programs, with the specific near-term focus on bringing our oral insulin (ORMD-0801) through regulatory approval and into commercialization,” stated ORAMED CEO, Nadav Kidron.
Dr. Simon Bruce is trained in Internal Medicine with sub-specialization in Endocrinology at the National Institutes of Health (NIH). At the NIH, he received training and conducted human patient-oriented clinical research. For the past 17 years, he has held positions of increasing responsibility in both large pharmaceutical and small to medium sized biotech companies. He has broad experience across all phases of clinical development and has been responsible for clinical development strategy and execution from pre-IND to first-in-human and Phase 1/2 proof-of-concept trials through Phase 3 planning, execution and filing. He has led clinical development of multiple compounds in the Metabolic and Diabetes therapeutic areas including DPP4 and SGLT2 inhibitors, GLP-1 agonists, leptin and prandial insulins among others. Most recently he served as Chief Medical Officer with Adocia Inc., working on an ultra-rapid insulin in collaboration with Eli Lilly.
For more information, see: www.oramed.com/oramed-appoints-dr-simon-bruce-as-vice-president-of-medical-affairs